Formation and clearance of TNF–TNF inhibitor complexes during TNF inhibitor treatment
British Journal of Pharmacology · 2024
DOI: 10.1111/bph.16269 ↗At a glance
Journal article in British Journal of Pharmacology, 2024. Written by Lea Catharina Berkhout and 13 co-authors. Institution: Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands. Major MEDLINE topics: Antirheumatic Agents, Arthritis, Rheumatoid. Cited 8 times so far (Crossref); 62 references. Funded by: ZonMw.
Abstract (original language)
Background and Purpose Millions of patients with inflammatory diseases are treated with tumour necrosis factor (TNF) inhibitors (TNFi). Individual treatment response varies, in part related to variable drug clearance. The role of TNF–TNFi complexes in clearance of the different TNFi is controversial. Moreover, mechanistic insight into the structural aspects and biological significance of TNF–TNFi complexes is lacking. We hypothesized a role for Fc‐mediated clearance of TNF–TNFi immune complexes. Therefore, we investigated circulating TNF–TNFi complexes upon treatment with certolizumab—lacking Fc tails—in comparison with adalimumab, golimumab, infliximab and etanercept. Experimental Approach Drug‐tolerant ELISAs were developed and used to quantify TNF during adalimumab, golimumab, etanercept, certolizumab and infliximab treatment in patients with inflammatory arthritis or ulcerative colitis for a maximum follow‐up of 1 year. Effects on in vitro TNF production and Fc‐mediated uptake of TNF–TNFi complexes were investigated for all five TNFi. Key Results Circulating TNF concentrations were >20‐fold higher during certolizumab treatment compared with adalimumab, reaching up to 23.1 ng·ml −1 . Internalization of TNF–TNFi complexes by macrophages depended on Fc valency, with efficient uptake for the full antibody TNFi (three Fc tails), but little or no uptake for etanercept and certolizumab (one and zero Fc tail, respectively). TNF production was not affected by TNFi. Total TNF load did not affect clearance rate of total TNFi. Conclusions and Implications Differences in TNFi structure profoundly affect clearance of TNF, while it is unlikely that TNF itself significantly contributes to target‐mediated drug disposition of TNFi.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Immunopathology, Sanquin Research, Amsterdam, The Netherlands.
- Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
- Amsterdam Rheumatology and Immunology Center | Reade, Amsterdam, The Netherlands.
- Department of Experimental Immunohematology, Sanquin Research, Amsterdam, The Netherlands.
- Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Therapeutic and Diagnostic Antibodies, Katholieke Universiteit Leuven, Leuven, Belgium.
- Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
ORCID profiles: Lea Catharina Berkhout, Theo Rispens
Funding
- ZonMw
Cite
APA
Berkhout, L. C., I'Ami, M. J., Kruithof, S., Vogelzang, E. H., Hooijberg, F., Hart, M. H. L., Bentlage, A. E. H., Thomas, D., Vermeire, S., Vidarsson, G., Ten Brinke, A., Nurmohamed, M. T., Wolbink, G. J., & Rispens, T. (2024). Formation and clearance of TNF–TNF inhibitor complexes during TNF inhibitor treatment. British Journal of Pharmacology. https://doi.org/10.1111/bph.16269
Vancouver
Berkhout LC, I'Ami MJ, Kruithof S, Vogelzang EH, Hooijberg F, Hart MHL, et al. Formation and clearance of TNF–TNF inhibitor complexes during TNF inhibitor treatment. British Journal of Pharmacology. 2024. doi:10.1111/bph.16269
BibTeX
@article{Berkhout2024,
author = {Berkhout, Lea Catharina and I'Ami, Merel Jeanne and Kruithof, Simone and Vogelzang, Erik Hans and Hooijberg, Femke and Hart, Margaretha Hendrika Louise and Bentlage, Arthur Ebel Herman and Thomas, Debby and Vermeire, Severine and Vidarsson, Gestur and Ten Brinke, Anja and Nurmohamed, Michael Twahier and Wolbink, Gerrit Jan and Rispens, Theo},
title = {Formation and clearance of TNF–TNF inhibitor complexes during TNF inhibitor treatment},
journal = {British Journal of Pharmacology},
year = {2024},
doi = {10.1111/bph.16269}
}
EUVIMED